Picture of MiMedx logo

MDXG MiMedx News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareAdventurousMid CapContrarian

MiMedx Group Inc expected to post earnings of 8 cents a share - Earnings Preview

* MiMedx Group Inc  MDXG.OQ   MDXG.O  is expected to show a
rise
in quarterly revenue when it reports  results on July 31 for the
period ending June 30 2024
    * The Marietta Georgia-based  company is expected to report
a
9.4% increase in revenue to $88.919 million from $81.26 million
a year ago, according to the mean estimate from 7 analysts,
based on LSEG data.
    * ​LSEG's mean analyst estimate for MiMedx Group Inc is for
earnings of 8 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 6 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for MiMedx
Group Inc
is $12.00​, above​ its last closing price of $7.76. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Jan. 1 0001   0.04        0.05       0.07      Beat    55.6
 Dec. 31 0001  0.07        0.07       0.32      Beat    357.1
 Sep. 30 2023  0.04        0.05       0.06      Beat    33.3​
 Jun. 30 2023  -0.02       -0.02      0.00      Beat    100
 ​​Mar.        -0.08       -0.09      -0.06     Beat    30.8
 31 2023                                                
 Dec. 31 2022  -0.04       -0.04      -0.02     Beat    45.5​
 Sep. 30 2022  -0.07       -0.08      -0.09     Missed  -16.1
 Jan. 1 0001   -0.05       -0.06      -0.11     Missed  -94.1
 This summary was machine generated July 29 at 21:06 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)

Recent news on MiMedx

See all news